Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
Research output: Contribution to journal › Editorial › Research › peer-review
Standard
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? / Holst, Jens Juul.
In: The Lancet, Vol. 394, No. 10192, 2019, p. 4-6.Research output: Contribution to journal › Editorial › Research › peer-review
Harvard
Holst, JJ 2019, 'Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?', The Lancet, vol. 394, no. 10192, pp. 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
APA
Holst, J. J. (2019). Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet, 394(10192), 4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
Vancouver
Holst JJ. Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist? The Lancet. 2019;394(10192):4-6. https://doi.org/10.1016/S0140-6736(19)31350-9
Author
Bibtex
@article{7a05639db93249f5ba8627597a941d90,
title = "Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?",
author = "Holst, {Jens Juul}",
year = "2019",
doi = "10.1016/S0140-6736(19)31350-9",
language = "English",
volume = "394",
pages = "4--6",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10192",
}
RIS
TY - JOUR
T1 - Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
AU - Holst, Jens Juul
PY - 2019
Y1 - 2019
U2 - 10.1016/S0140-6736(19)31350-9
DO - 10.1016/S0140-6736(19)31350-9
M3 - Editorial
VL - 394
SP - 4
EP - 6
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10192
ER -
ID: 225957791